MediWound (MDWD) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MediWound (MDWD) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 26.7% versus a loss of 73.0%. Over five years, MDWD leads with a -46.2% price change compared with -97.9% for NBP. MediWound is the larger company by market cap ($160.3 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | NBP |
|---|---|---|
| Share price | $12.42 | $1.37 |
| Market cap | $160.35M | $158.92M |
| 1-day change | -3.35% | 0.00% |
| YTD return | -30.39% | -65.58% |
| 1-year return | -26.74% | -72.98% |
| 5-year return | -46.17% | -97.92% |
| EPS (TTM) | $-2.17 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $6.79 |
| 52-week low | $12.42 | $1.31 |
| Distance from 52-week high | -37.99% | -79.82% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +146.94% | +556.93% |
| Average volume | 84.01K | 387.00K |
| Shares outstanding | 12.91M | 116.00M |
| Employees | 121 | 30 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDWD has outperformed NBP by 46.2 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
MDWD vs NBP FAQ
Which is bigger, MediWound or NovaBridge Biosciences?
MediWound (MDWD) is larger, with a market capitalization of $160.35M compared with $158.92M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, MDWD or NBP?
MDWD returned -26.74% over the past 12 months, compared with -72.98% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and NovaBridge Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for MediWound and Biotechnology: Pharmaceutical Preparations for NovaBridge Biosciences.